Monopar Therapeutics (NASDAQ:MNPR) Rating Lowered to “Hold” at Zacks Research

Monopar Therapeutics (NASDAQ:MNPR) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued on Thursday,Zacks.com reports.

MNPR has been the topic of several other research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Cantor Fitzgerald lowered Monopar Therapeutics from an “overweight” rating to a “neutral” rating and upped their target price for the company from $109.00 to $119.00 in a report on Thursday. BTIG Research increased their price target on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday. Piper Sandler set a $105.00 price target on Monopar Therapeutics in a report on Tuesday, June 2nd. Finally, Barclays restated an “overweight” rating and set a $128.00 price objective (up from $125.00) on shares of Monopar Therapeutics in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $117.42.

Monopar Therapeutics Price Performance

Monopar Therapeutics stock opened at $113.04 on Thursday. Monopar Therapeutics has a 12 month low of $29.18 and a 12 month high of $124.82. The company has a fifty day moving average price of $96.11 and a two-hundred day moving average price of $71.53. The company has a market cap of $757.25 million, a PE ratio of -52.09 and a beta of 1.47.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.02. Equities research analysts anticipate that Monopar Therapeutics will post -2.95 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics in the third quarter valued at approximately $18,904,000. Siren L.L.C. acquired a new position in shares of Monopar Therapeutics during the fourth quarter worth approximately $13,863,000. Deerfield Management Company L.P. acquired a new position in shares of Monopar Therapeutics during the third quarter worth approximately $13,048,000. RA Capital Management L.P. grew its holdings in Monopar Therapeutics by 30.5% in the 4th quarter. RA Capital Management L.P. now owns 667,207 shares of the company’s stock worth $43,569,000 after buying an additional 156,000 shares in the last quarter. Finally, TCG Crossover Management LLC bought a new position in Monopar Therapeutics in the 3rd quarter worth approximately $12,496,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.